Page last updated: 2024-11-08

roxithromycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(E)-roxithromycin : A major geometrical isomer of roxithromycin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID444037
CHEMBL ID1476500
CHEBI ID48844
PubMed CID6915744
CHEMBL ID1214185
CHEBI ID48935
SCHEMBL ID65985
MeSH IDM0023927

Synonyms (109)

Synonym
DIVK1C_000382
KBIO1_000382
SPECTRUM_001653
SMP1_000054
BCBCMAP01_000131
KBIO2_007269
KBIO2_002133
KBIO2_004701
KBIOSS_002133
KBIO3_002217
KBIOGR_000779
SPBIO_001422
SPECTRUM3_001159
NINDS_000382
SPECTRUM4_000200
SPECTRUM2_001551
MLS001304008 ,
smr000718779
CHEBI:48844 ,
(3r,4s,5s,6r,7r,9r,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxa
dtxsid8041117 ,
HMS2236F08
CHEMBL1476500
(3r,4s,5s,6r,7r,9r,10z,11s,12r,13s,14r)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
CHEMBL1214185
nsc-758443
ru-965
ccris 3461
roxitromicina [spanish]
erythromycin, 9-(o-((2-methoxyethoxy)methyl)oxime), (9e)-
erythromycin, 9-(o-((2-methoxyethoxy)methyl)oxime)
erythromycin 9-(o-((2-methoxyethoxy)methyl)oxime)
roxithromycinum [latin]
roxithromycine [french]
9-(o-((2-methoxyethoxy)methyl)oxime)erythromycin
brn 4286925
cas-80214-83-1
NCGC00016942-01
IDI1_000382
SPECTRUM5_001058
BSPBIO_002717
NCGC00178510-01
(3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-
ru 28965
9-[o-[(2-methoxyethoxy)methyl]oxime]erythromycin, (9e)-
ru 965
rc2952
DB00778
(9e)-erythromycin 9-(o-((2-methoxyethoxy)methyl)oxime)
D01710
rulide (tn)
roxithromycin (jp17/usan/inn)
SPECTRUM1503276
(3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-10-{[(2-methoxyethoxy)m
(3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-4-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-10-{[(2-methoxyethoxy)methoxy]imino}-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyloxy]-3,5,7,9,11,13-he
roxithromycine
(e)-roxithromycin
9-[o-(2-methoxyethoxymethyl)-oxime] of erythromycin
(3r,4s,5s,6r,7r,9r,11s,12r,13s,14r)-4-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-10-{[(2-methoxyethoxy)methoxy]imino}-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexame
CHEBI:48935 ,
roxitromicina
roxithromycinum
HMS2093C11
HMS501D04
HMS1922O19
NCGC00182077-02
(3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl
unii-21kof230fa
nsc 758443
roxithromycin [usan:inn:ban:jan]
21kof230fa ,
tox21_301835
NCGC00255408-01
dtxcid6021117
tox21_113150
nsc758443
pharmakon1600-01503276
tox21_110697
AKOS015969730
CCG-39329
roxithromycin [ep impurity]
roxithromycin [mi]
erythromycin 9-(e)-(o-((2-methoxyethoxy)methyl)oxime)
roxithromycin [ep monograph]
(e)-erythromycin-9-(o-((2-methoxyethoxy)methyl)oxime)
roxithromycin [mart.]
roxithromycin [jan]
(3r,4s,5s,6r,7r,9r,11s,12r,13s,14r)-4-((2,6dideoxy-3-c-methyl-3-o-methyl-.alpha.-l-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-10-((e)((2-methoxyethoxy)methoxy)imino)-3,5,7,9,11,13hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-.beta.-d-xylohexopy
erythromycin 9-[o-[(2-methoxyethoxy)methyl]oxime]
roxithromycin [who-dd]
erythromycin a, 9-(o-(2-methoxyethoxymethyl)-oxime)
roxithromycin [inn]
roxithromycin [usan]
HY-B0435
SCHEMBL65985
AB00052342_02
sr-05000001850
SR-05000001850-2
SR-05000001850-1
SBI-0051809.P002
HMS3714L09
(3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethy
bdbm50248154
Q27895851
(3r,4s,5s,6r,7r,9r,11s,12r,13s,14r,e)-6-(((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-10-(((2-methoxyethoxy)met
roxithromycin,(s)
9-[o-[(2-methoxyethoxy)methyl]oxime]erythromycin
BRD-K38684403-001-03-9
BRD-K38684403-001-05-4

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Bharate, SS; Vishwakarma, RA, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
erythromycin derivative
macrolideA macrocyclic lactone with a ring of twelve or more members derived from a polyketide.
semisynthetic derivativeAny organic molecular entity derived from a natural product by partial chemical synthesis.
roxithromycinSemisynthetic derivative of erythromycin A.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Roxithromycin Action Pathway14

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency17.78280.044717.8581100.0000AID485341
TDP1 proteinHomo sapiens (human)Potency18.20030.000811.382244.6684AID686978; AID686979
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency6.30960.28189.721235.4813AID2326
VprHuman immunodeficiency virus 1Potency63.09571.584919.626463.0957AID651644
Alpha-synucleinHomo sapiens (human)Potency6.30960.56239.398525.1189AID652106
TDP1 proteinHomo sapiens (human)Potency7.79780.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency8.33770.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency40.42910.000221.22318,912.5098AID743054
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency17.30370.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency30.77080.001530.607315,848.9004AID1224848; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency14.34480.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.68220.000229.305416,493.5996AID743069
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency26.32040.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency32.39760.042027.378961.6448AID743210
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)0.06000.06008.9128130.5170AID1902
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (117)

Processvia Protein(s)Taxonomy
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (49)

Processvia Protein(s)Taxonomy
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (161)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID278858Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID326087Antimicrobial activity against Streptococcus pneumoniae NMU112 infected in po dosed CBA/J mouse blood assessed as number of colony forming units after 6 days relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID283559Antibacterial activity against Escherichia coli AG102MB after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID326088Antimicrobial activity against Streptococcus pneumoniae NMU112 infected in po dosed CBA/J mouse blood assessed as number of colony forming units after 7 days relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326090Antimicrobial activity against Streptococcus pneumoniae NMU112 infected in po dosed CBA/J mouse bronchoalveolar lavage fluid assessed as reduction in number of colony forming units after 24 to 48 hrs relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID641634Antibacterial activity against Bordetella bronchiseptica ATCC 10580 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID321877Elimination half life in human at 150 mg, po administered as single dose2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
A new insight into solid-state conformation of macrolide antibiotics.
AID1403741Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 after overnight incubation by microbroth dilution method2018European journal of medicinal chemistry, Feb-10, Volume: 145Amino acid conjugated antimicrobial drugs: Synthesis, lipophilicity- activity relationship, antibacterial and urease inhibition activity.
AID326098Reduction of pneumococcal surface protein A in Streptococcus pneumoniae NMU112 infected CBA/J mouse lung lysates after 48 hrs by Western blot relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID36452Alpha-1-glycoprotein binding ability was measured1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A comparative NMR study between the macrolide antibiotic roxithromycin and erythromycin A with different biological properties.
AID326074Antimicrobial activity against drug-resistant Streptococcus pneumoniae NMU112 infected CBA/J mouse assessed as median survival time at 5 mg/kg, po relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326069Reduction of pneumolysin production in Streptococcus pneumoniae NMU112 lysates at 5 ug/mL after 12 hrs by Western blot relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID278989Antibacterial activity against Pseudomonas sp. B13 GFP1 containing multiresistance plasmid pRSB1012007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID519672Effect on PAR2 gene expression in normal human epidermal keratinocytes assessed as effect on cell viability at 10 uM after 72 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.
AID16672Percentage ionization was measured1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A comparative NMR study between the macrolide antibiotic roxithromycin and erythromycin A with different biological properties.
AID326101Inhibition of Streptococcus pneumoniae NMU112 infection-induced polymorphonuclear leukocytes infiltration in CBA/J mouse lung assessed as MPO activity after 12 hrs relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1184221Antibacterial activity against Bordetella bronchiseptica ATCC 4617 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID278991Antibacterial activity against Escherichia coli DH5-alpha containing pUC182007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID326103Antimicrobial activity against Streptococcus pneumoniae NMUP45 infected CBA/J mouse assessed as animal survival at => 5 mg/kg, po relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1403737Antibacterial activity against Staphylococcus aureus ATCC 6538 after overnight incubation by microbroth dilution method2018European journal of medicinal chemistry, Feb-10, Volume: 145Amino acid conjugated antimicrobial drugs: Synthesis, lipophilicity- activity relationship, antibacterial and urease inhibition activity.
AID326071Inhibition of pneumococcal surface protein A production in Streptococcus pneumoniae NMU112 lysates at 5 ug/mL after 12 hrs by Western blot relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326080Drug level in Streptococcus pneumoniae NMU112 infected CBA/J mouse plasma at 5 mg/kg/day, po after 48 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326093Increase in Streptococcus pneumoniae NMU112 infection-induced reduction in MCP1 level in po dosed CBA/J mouse lung after 12 to 36 hrs by sandwich ELISA relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1602078Antibacterial activity against Staphylococcus aureus ATCC 6538 measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID326073Antimicrobial activity against drug-resistant Streptococcus pneumoniae NMU112 infected CBA/J mouse assessed as median survival time at 10 mg/kg, po relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326089Antimicrobial activity against Streptococcus pneumoniae NMU112 infected in po dosed CBA/J mouse lungs assessed as reduction in number of colony forming units after 24 to 48 hr relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID278857Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID278860Antiproliferative effect against HeLa cells after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID558081Inhibition of PAR2-mediated TNFalpha and SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 10 uM by ELISA2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID278859Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID326092Reduction in Streptococcus pneumoniae NMU112 infection-induced elevation in keratinocyte-derived chemokine level in po dosed CBA/J mouse lung after 12 hrs by sandwich ELISA relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID278861Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID278855Cytotoxicity against primary human osteoblasts at 200 ug/ml assessed as LDH release after 24 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID1482267Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID365693Antimicrobial activity against Enterobacter aerogenes ATCC 13048 assessed as inhibition zone diameter after 24 hrs by agar well diffusion method2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
AID519670Toxicity in normal human epidermal keratinocytes assessed as effect on cell viability at 10 uM after 72 hrs by colorimetric assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.
AID278853Cytotoxicity against primary human osteoblasts at 400 ug/ml assessed as LDH release after 24 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID321878Lipophilicity, log D at pH 8.02008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
A new insight into solid-state conformation of macrolide antibiotics.
AID326097Reduction of pneumolysin production in Streptococcus pneumoniae NMU112 infected CBA/J mouse lung lysates after 48 hrs of infection by Western blot relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID283560Antibacterial activity against Escherichia coli HNCE4 after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID326067Antimicrobial activity against Streptococcus pneumoniae NMUP452007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID518962Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZ7 lacking codons 2 to 4 with additional mutations leader peptide cistrons reporter plasmid at 25 mg/ml after 36 hrs at 37 degC by disc-based be2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of erm(C) expression by noninducing antibiotics.
AID326086Antimicrobial activity against Streptococcus pneumoniae NMU112 infected in po dosed CBA/J mouse blood assessed as number of colony forming units after 5 days relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID519664Inhibition of PAR2-mediated IL1-beta and SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 10 uM by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID326066Antimicrobial activity against Streptococcus pneumoniae NMU1122007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1190001Inhibition of cell proliferation of HUVEC at 12.5 to 200 uM after 72 hrs by MTS assay2015European journal of medicinal chemistry, Jan-27, Volume: 90Multimodal biopanning of T7 phage-displayed peptides reveals angiomotin as a potential receptor of the anti-angiogenic macrolide Roxithromycin.
AID278993Antibacterial activity against Escherichia coli DH5-alpha containing macrolide-resistant pUC18-mrx(E) region2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID326099Reduction of polymorphonuclear leukocytes in UV rays killed Streptococcus pneumoniae NMU112 infected CBA/J mouse bronchoalveolar lavage fluid relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326104Reduction in Streptococcus pneumoniae NMU112 infection induced elevation in syndecan-1 shedding in po dosed CBA/J mouse bronchoalveolar lavage fluid relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID278854Cytotoxicity against primary human osteoblasts at 100 ug/ml assessed as LDH release after 24 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID641639Antibacterial activity against Staphylococcus aureus ATCC 6538 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID278988Antibacterial activity against Pseudomonas sp. B13 GFP12007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID321874Tmax in human at 150 mg, po administered as single dose2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
A new insight into solid-state conformation of macrolide antibiotics.
AID1193499Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1403739Antibacterial activity against Escherichia coli ATCC 25922 after overnight incubation by microbroth dilution method2018European journal of medicinal chemistry, Feb-10, Volume: 145Amino acid conjugated antimicrobial drugs: Synthesis, lipophilicity- activity relationship, antibacterial and urease inhibition activity.
AID321872Oral bioavailability in human at 150 mg administered as single dose2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
A new insight into solid-state conformation of macrolide antibiotics.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID326068Antimicrobial activity against Streptococcus pneumoniae NMU6052007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326081Drug level in Streptococcus pneumoniae NMU112 infected CBA/J mouse plasma at 5 mg/kg/day, po after 72 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID326082Drug level in Streptococcus pneumoniae NMU112 infected CBA/J mouse lung tissue at 5 mg/kg/day, po after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID26090pKa was measured1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A comparative NMR study between the macrolide antibiotic roxithromycin and erythromycin A with different biological properties.
AID283558Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1190000Binding affinity to recombinant GST-tagged Amot (H343 to I675 residues) (unknown origin) expressed in Escherichia coli at 50 uM using Amot immobilized on gold electrode of QCM sensor chip by WCM biosensor-based assay2015European journal of medicinal chemistry, Jan-27, Volume: 90Multimodal biopanning of T7 phage-displayed peptides reveals angiomotin as a potential receptor of the anti-angiogenic macrolide Roxithromycin.
AID278856Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID365692Antimicrobial activity against Micrococcus luteus assessed as inhibition zone diameter after 24 hrs by agar well diffusion method2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
AID519673Effect on PAR2 gene expression in normal human epidermal keratinocytes assessed as effect on cell viability at 100 uM after 72 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.
AID519665Inhibition of PAR2-mediated SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 10 uM preincubated for 24 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.
AID326076Antimicrobial activity against drug-resistant Streptococcus pneumoniae NMU112 infected CBA/J mouse assessed as animal survival at 1.25 mg/kg, po2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1184220Antibacterial activity against Salmonella typhimurium ATCC 14028 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID1193494Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193492Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID326079Drug level in Streptococcus pneumoniae NMU112 infected CBA/J mouse plasma at 5 mg/kg/day, po after 24 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID641638Antibacterial activity against Micrococcus luteus ATCC 10240 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID365691Antimicrobial activity against Salmonella setubal ATCC 19196 assessed as inhibition zone diameter after 24 hrs by agar well diffusion method2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
AID1189999Binding affinity to recombinant GST-tagged Amot (H343 to I675 residues) (unknown origin) expressed in Escherichia coli at 25 uM using Amot immobilized on gold electrode of QCM sensor chip by WCM biosensor-based assay2015European journal of medicinal chemistry, Jan-27, Volume: 90Multimodal biopanning of T7 phage-displayed peptides reveals angiomotin as a potential receptor of the anti-angiogenic macrolide Roxithromycin.
AID321876Protein binding in human plasma2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
A new insight into solid-state conformation of macrolide antibiotics.
AID1403740Antibacterial activity against Salmonella typhimurium ATCC 14028 after overnight incubation by microbroth dilution method2018European journal of medicinal chemistry, Feb-10, Volume: 145Amino acid conjugated antimicrobial drugs: Synthesis, lipophilicity- activity relationship, antibacterial and urease inhibition activity.
AID321875AUC in human at 150 mg, po administered as single dose2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
A new insight into solid-state conformation of macrolide antibiotics.
AID278992Antibacterial activity against Escherichia coli DH5-alpha containing macrolide-resistant pUC18-mph(E) region2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID1403738Antibacterial activity against Bacillus subtilis ATCC 6633 after overnight incubation by microbroth dilution method2018European journal of medicinal chemistry, Feb-10, Volume: 145Amino acid conjugated antimicrobial drugs: Synthesis, lipophilicity- activity relationship, antibacterial and urease inhibition activity.
AID641637Antibacterial activity against Escherichia coli ATCC 15224 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID326084Drug level in Streptococcus pneumoniae NMU112 infected CBA/J mouse lung tissue at 5 mg/kg/day, po after 72 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID278994Antibacterial activity against Escherichia coli DH5alpha containing macrolide-resistant pUC18-mph(E)-mrx(E) region2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID1184217Antibacterial activity against Escherichia coli ATCC 15224 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1193493Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1193495Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID519666Inhibition of PAR2-mediated SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 100 uM preincubated for 24 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID641636Antibacterial activity against Salmonella typhi ATCC 6539 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID326083Drug level in Streptococcus pneumoniae NMU112 infected CBA/J mouse lung tissue at 5 mg/kg/day, po after 48 hrs2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1184222Antibacterial activity against Bacillus subtilis ATCC 6633 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID19635Partition coefficient (logP)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A comparative NMR study between the macrolide antibiotic roxithromycin and erythromycin A with different biological properties.
AID16043Serum protein binding ability was measured1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A comparative NMR study between the macrolide antibiotic roxithromycin and erythromycin A with different biological properties.
AID365689Antimicrobial activity against Escherichia coli ATCC 1522 assessed as inhibition zone diameter after 24 hrs by agar well diffusion method2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID326085Antimicrobial activity against Streptococcus pneumoniae NMU112 infected in po dosed CBA/J mouse blood assessed as number of colony forming units after 4 days relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326102Antimicrobial activity against Streptococcus pneumoniae NMU605 infected CBA/J mouse assessed as animal survival at => 2.5 mg/kg, po relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1193496Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID278990Antibacterial activity against Pseudomonas sp. B13 GFP1 containing macrolide resistance plasmid pRSB1112007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID1193498Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID641635Antibacterial activity against Enterobacter aerogenes ATCC 13048 at 1 mg/ml after 24 hrs by agar well diffusion method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1184218Antibacterial activity against Staphylococcus aureus ATCC 6538 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID326100Reduction of MMP7 expression level in UV rays killed Streptococcus pneumoniae NMU112 infected CBA/J mouse bronchoalveolar lavage fluid relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326095Increase in Streptococcus pneumoniae NMU112 infection-induced reduction in MCP1 level in po dosed CBA/J mouse lung after 8 hrs by sandwich ELISA relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1193497Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID321873Cmax in human at 150 mg, po administered as single dose2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
A new insight into solid-state conformation of macrolide antibiotics.
AID519671Toxicity in normal human epidermal keratinocytes assessed as effect on cell viability at 100 uM after 72 hrs by colorimetric assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1184219Antibacterial activity against Enterobacter aerogenes ATCC 13048 at 40 mg/mL after 24 hrs by disc diffusion method2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID326096Inhibition of Streptococcus pneumoniae NMU112 induced MMP7 expression level in po dosed CBA/J mouse assessed as decrease in caseinolytic activity after 6 to 48 hrs relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID326094Reduction in Streptococcus pneumoniae NMU112 infection-induced elevation in keratinocyte-derived chemokine level in po dosed CBA/J mouse bronchoalveolar lavage fluid after 8 hrs by sandwich ELISA relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID365690Antimicrobial activity against Bordetella bronchiseptica ATCC 4617 assessed as inhibition zone diameter after 24 hrs by agar well diffusion method2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
AID326078Antimicrobial activity against Streptococcus pneumoniae NMU112 infected CBA/J mouse lung extract assessed as reduction in colony forming units at 10 mg/kg/day, po after 1 hr2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID518970Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZdelta2-4 mutant leader peptide cistrons reporter plasmid at 25 mg/ml after 36 hrs at 37 degC by disc-based beta-galactosidase reporter gene ass2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of erm(C) expression by noninducing antibiotics.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID326077Antimicrobial activity against drug-resistant Streptococcus pneumoniae NMU112 infected CBA/J mouse assessed as median survival time at 7.5 mg/kg, po relative to control2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.13)18.2507
2000's10 (31.25)29.6817
2010's19 (59.38)24.3611
2020's2 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 89.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index89.89 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index153.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (89.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome [NCT03148444]Phase 4400 participants (Anticipated)Interventional2017-06-01Not yet recruiting
Double-Blind, Placebo-Controlled Study of Three-Month Treatment With the Combination of Ofloxacin and Roxithromycin in Recent-Onset Reactive Arthritis [NCT00621387]56 participants (Actual)Interventional1993-11-30Completed
Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial [NCT02819570]Phase 4400 participants (Anticipated)Interventional2015-11-30Recruiting
Effects of Roxithromycin on Quality of Life and Physiologic Outcomes in Bronchiectasis Patients During Treatment and Posttreatment Period [NCT04122040]Phase 340 participants (Actual)Interventional2011-03-01Completed
Treatment of Rheumatoid Arthritis With Roxithromycin [NCT00439062]Phase 4100 participants Interventional2006-06-30Completed
The Study for New Effect of Roxithromycin on Androgenetic Alopecia. [NCT00197379]20 participants (Anticipated)Interventional2005-05-31Active, not recruiting
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA): A Study Of Personalized Diagnosis of Primary Aldosteronism With Implications For Treatment [NCT03414918]342 participants (Anticipated)Interventional2018-03-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]